Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Ruizhou Biotechnology

Request full access

Advanced pneumococcal conjugate vaccines for broader pathogenic coverage

ChinaFounded 2017Biotech & Life Sciences

About Shanghai Ruizhou Biotechnology

Shanghai Ruizhou Biotechnology Co., Ltd. is a biopharmaceutical company established in September 2017 by Dr. Xianchao Zhu, a returning expert from the US. The company focuses on the research, development, and industrialization of innovative vaccines and recombinant protein biologies. Dr. Zhu, a University of California biology PhD, has over two decades of experience in new drug and vaccine development at leading global pharmaceutical companies like Pfizer and later served as a department head at the US Pharmacopoeia's R&D center in China. His extensive background includes leading over 25 new drug development projects, with three achieving FDA market approval.

The company's core product is a self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24). This vaccine was created to address the specific pathogenic strains prevalent in China and aims to increase protection coverage from the current 75% to over 90%. It utilizes a novel non-toxic dual-protein carrier technology. Ruizhou Bio has received clinical approval for the vaccine across all age groups. As of June 2025, the clinical research for adults has completed Phase II trials, with Phase III set to begin, while the Phase I trial for infants and young children has yielded initial data.

Ruizhou Biotechnology has secured significant funding, including a strategic investment in 2017 from Changchun High-Tech Group, which, along with its subsidiary BCHT Biotechnology, has invested a total of 316 million RMB for a 50% stake. More recently, the company completed a Series A+ financing round of tens of millions of RMB in June 2025, led by Changxing Fund. To manage its entire value chain, Ruizhou established Shanghai Weizhou Biotechnology in March 2021, a GMP-level pilot R&D and production workshop in Shanghai. Furthermore, it founded Changchun Ruizhou Biopharmaceutical Co., Ltd. in May 2020 to construct a large-scale, international-standard GMP production base in Changchun, with a potential annual capacity of over 100 million vaccine doses.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
1
Dealroom signal
44.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Drug Development, Vaccines, biomanufacturing, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jan 2026 $28M $110M Undisclosed ↗
SERIES A✓Equity / VC Jun 2025 $2.8M $11M Changxing Fund ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Ruizhou Biotechnology team growth

Shanghai Ruizhou Biotechnology's team grew 20% over the past year.

1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Ruizhou Biotechnology in its local ecosystem

Live from Dealroom

The Shanghai Ruizhou Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Changxing Fund
Employees 6 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Ruizhou Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Ruizhou Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.